A. Gottardi

发表

Microarray analyses and molecular profiling of steatosis induction in immortalized human hepatocytes

M. Vinciguerra, V. Pazienza, P. Pugnale, 2007, Laboratory Investigation.

Elevated Liver Regeneration in Response to Pharmacological Reduction of Elevated Portal Venous Pressure by Terlipressin After Partial Hepatectomy

D. Candinas, M. Montani, G. Beldi, 2014, Transplantation.

Reply to: Bile salt export pump expression: Can immunohistochemistry in isolation mislead?

M. Montani, A. Gottardi, S. Moghadamrad, 2014 .

Attenuated fibrosis in specific pathogen‐free microbiota in experimental cholestasis‐ and toxin‐induced liver injury

J. Kirundi, K. McCoy, A. Gottardi, 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Pathophysiology of portal hypertension and variceal bleeding

J. Bosch, A. Berzigotti, F. Schepis, 2009 .

Emerging future therapies for portal hypertension

J. Bosch, A. Gottardi, 2008 .

Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study

F. Nevens, S. Sarin, D. Valla, 2020, Hepatology.

NCX-1000, a Nitric Oxide–Releasing Derivative of UDCA, Does Not Decrease Portal Pressure in Patients With Cirrhosis: Results of a Randomized, Double-Blind, Dose-Escalating Study

J. Bosch, C. Gagnon, A. Berzigotti, 2010, The American Journal of Gastroenterology.

BRIEF COMMUNICATION Risk of Complications After Abdominal Paracentesis in Cirrhotic Patients: A Prospective Study

L. Spahr, A. Hadengue, F. Torres, 2009 .

Acute-on Chronic Liver Failure (ACLF): A distinct clinical syndrome

R. Moreau, R. Jalan, J. Trebicka, 2012 .

1404 DIAGNOSIS, PREVALENCE, AND PROGNOSIS OF ACUTE-ON- CHRONIC LIVER FAILURE (ACLF): RESULTS OF THE EASL-CHRONIC LIVER FAILURE (CLIF) CONSORTIUM CANONIC STUDY

R. Moreau, R. Jalan, J. Trebicka, 2012 .

Polymorphonuclear leukocyte count in spontaneous bacterial peritonitis.

A. Gottardi, 2008 .

Idiopathic Non-cirrhotic Portal Hypertension and Close Entities: a Need for Clarifying Terminology

P. Rautou, A. Gottardi, 2017, Current Hepatology Reports.

Rifampicin, a general review.

E. Domenichini, G. Binda, A. Gottardi, 1971, Arzneimittel-Forschung.

Genotypically controlled behaviour of embryonic cells of Drosophila melanogaster cultured in vitro.

G. R. Raimondi, A. Gottardi, 1967, Journal of insect physiology.

Changes of chromosome number in cells ofDrosophila melanogaster cultured in vitro

S. Dolfini, A. Gottardi, 1966, Experientia.

Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells.

Francesco Negro, Christine Rossi, Andrea De Gottardi, 2006, Journal of virological methods.

FxR-modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis

David Stutz, M. Rescigno, B. Yilmaz, 2019 .

4-O′-methylhonokiol protects from alcohol/carbon tetrachloride-induced liver injury in mice

J. Hampe, V. Petrucci, J. Gertsch, 2017, Journal of Molecular Medicine.

Treatment of refractory ascites with an automated low flow ascites pump in patients awaiting liver transplantation

G. Stirnimann, V. Banz, F. Storni, 2021, Journal of Liver Transplantation.

Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: Outcomes and complications

J. Bosch, A. Berzigotti, Valerie Will, 2020, United European gastroenterology journal.

P523 SAFETY AND EFFICACY OF AN AUTOMATED LOW FLOW ASCITES (ALFA) PUMP IN CIRRHOTIC PATIENTS WITH REFRACTORY ASCITES

F. Lammert, T. Berg, J. Dufour, 2014 .

Coagulopathy of chronic liver disease.

A. Gottardi, 2011 .

Treatment of Malignant Ascites Using an Automated Pump Device

G. Stirnimann, V. Banz, F. Storni, 2018, American Journal of Gastroenterology.

Treatment of refractory ascites with an automated low‐flow ascites pump in patients with cirrhosis

F. Lammert, T. Berg, A. de Gottardi, 2017, Alimentary pharmacology & therapeutics.

Critical review of the use of erythropoietin in the treatment of anaemia during therapy for chronic hepatitis C

A. de Gottardi, F. Negro, M. Heim, 2012, Journal of viral hepatitis.

Peroxisome proliferator‐activated receptor‐α and ‐γ mRNA levels are reduced in chronic hepatitis C with steatosis and genotype 3 infection

V. Pazienza, A. de Gottardi, P. Pugnale, 2006 .

Review article: the modern management of portal hypertension – primary and secondary prophylaxis of variceal bleeding in cirrhotic patients

A. de Gottardi, J. Bosch, J. García‐Pagán, 2008, Alimentary pharmacology & therapeutics.

Transplantation hépatique – qui, quand, comment?

J. Dufour, D. Candinas, G. Beldi, 2014 .

Intestinal mucus and gut-vascular barrier: FxR-modulated entry sites for pathological bacterial translocation in liver cirrhosis

David Stutz, A. de Gottardi, M. Rescigno, 2019, bioRxiv.

Efficacy of Albumin Treatment for Patients with Cirrhosis and Infections Unrelated to Spontaneous Bacterial Peritonitis.

A. de Gottardi, R. Moreau, J. Trebicka, 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Isoproterenol Disrupts Intestinal Barriers Activating Gut-Liver-Axis: Effects on Intestinal Mucus and Vascular Barrier as Entry Sites

A. de Gottardi, M. Rescigno, M. Sorribas, 2019, Digestion.

P476 SHORT-TERM (28-DAY) CLINICAL COURSE AND TRANSPLANT-FREE MORTALITY IN ACUTE ON CHRONIC LIVER FAILURE (ACLF); EVIDENCE FOR REVERSIBILITY OF ACLF (A STUDY FROM THE CANONIC DATABASE)

R. Moreau, R. Jalan, J. Trebicka, 2014 .